Can a Two-Drug antiviral combo boost survival in liver cancer patients?
NCT ID NCT07253220
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study compares two antiviral strategies—one using a single drug (TAF) and the other starting with two drugs (entecavir plus TAF) then switching to TAF alone—in 120 people with advanced hepatitis B-related liver cancer who are also receiving immunotherapy. The main goal is to see which approach leads to better survival at 24 months. Researchers will also track virus levels and liver function over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenofovir alafenamide (TAF) and entecavir (ETV)
What this could lead to
If successful, this could show that combining two antivirals before switching to one helps people with hepatitis B-related liver cancer live longer during immunotherapy.
What could go wrong
This is a small, early-stage study with only 120 participants, so results may not apply to everyone. The trial hasn't started yet, and it's unclear if one strategy is truly better.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.